Adaptive Deep Brain Stimulation for Parkinson’s disease: Safety and effectiveness
| Autor: | T. Bocci, M. Arlotti, S. Marceglia, M. Prenassi, G. Ardolino, F. Cogiamanian, L. Borrellini, P. Rampini, M. Locatelli, S. Barbieri, A. Priori |
|---|---|
| Přispěvatelé: | Bocci, T., Arlotti, M., Marceglia, S., Prenassi, M., Ardolino, G., Cogiamanian, F., Borrellini, L., Rampini, P., Locatelli, Martina, Barbieri, S., Priori, A. |
| Rok vydání: | 2019 |
| Předmět: |
Levodopa
medicine.medical_specialty Deep brain stimulation Parkinson's disease Deep Brain Stimulation medicine.medical_treatment DBS 050105 experimental psychology 03 medical and health sciences 0302 clinical medicine Physical medicine and rehabilitation Rating scale Physiology (medical) Medicine 0501 psychology and cognitive sciences Parkinson's Disease aDBS business.industry 05 social sciences Levodopa therapy medicine.disease Sensory Systems nervous system diseases Brain Stimulation Neurology Dyskinesia Brain stimulation Neurology (clinical) medicine.symptom business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Clinical Neurophysiology. 130:e17 |
| ISSN: | 1388-2457 |
| Popis: | Deep Brain Stimulation (DBS) is an effective therapy for Parkinson’s disease (PD). We assessed the effectiveness of adaptive DBS (aDBS), that uses beta-band power of the subthalamic Local Field Potentials (LFPs) as target to adapt DBS parameters to motor fluctuations. In a first experiment, aDBS plus levodopa versus levodopa alone was studied; in a second phase, we evaluated aDBS versus cDBS. The experiments took place 5 days after implantation and lasted 2 days (Day 5 and 6, eight hours per day). Changes in the Unified Parkinson’s Disease Rating Scale (UPDRSIII) and Rush Dyskinesia Rating Scale were assessed. In the first experiment, in Day 5 DBS was turned OFF, while in Day 6 aDBS stimulation was turned on. In the second, cDBS was turned ON during Day 5 and aDBS turned ON during Day 6. aDBS improved UPDRSIII score compared to levodopa (three-way ANOVA, “day”x“medication” p = 0.003). Rush-DRS score from baseline was lower in aDBS patients than in cDBS (Wilcoxon-Mann-Whitney test: p aDBS was effective in controlling the patients PD symptoms in addition to the normal Levodopa therapy, reducing dyskinesias compared to cDBS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect